1	NATIONAL INSTITUTE FOR HEALTH AND CARE
2	EXCELLENCE
3	Scope for guideline update (starting 2024)
4 5	Urinary tract infection (recurrent): antimicrobial prescribing
6	NICE is updating its guideline on urinary tract infection (recurrent): antimicrobial
7	prescribing (NG112). The guideline was originally published in October 2018.
8	New evidence on the use of methenamine hippurate as an alternative to antibiotic
9	prophylaxis for treating recurrent urinary tract infections (UTIs) suggests that we may
10	need to update existing recommendations, or make new recommendations. Full
11	details are set out in the August 2022 surveillance review decision. The update will
12	be developed using the methods and processes in <u>developing NICE guidelines: the</u>
13	manual.
14	1 Who the guideline update covers
15	The current guideline covers people with recurrent UTIs who do not have a catheter.
16	UTIs are classified as recurrent in adults if they have at least:
17	• 2 or more UTIs in 6 months, or
18	• 3 or more UTIs in 12 months (European Association of Urology [EAU] guidelines
19	on urological infections [2017])
20	UTIs are classified as recurrent in children and young people under 16 years if they
21	have:
22	2 or more episodes of UTI with acute pyelonephritis/upper UTI, or
23	• 1 episode of UTI with acute pyelonephritis/upper UTI plus 1 or more episode of
24	UTI with cystitis/lower UTI, or

NICE guideline update: Urinary tract infection (recurrent): antimicrobial prescribing scope 1 of 3

These definitions are from the 2018 guideline. The update will focus on the use of

• 3 or more episodes of UTI with cystitis/lower UTI

methenamine hippurate for these groups.

25

26

27

1 Equality considerations

- 2 The equality and health inequalities assessment for the guideline update [hyperlink]
- 3 to the update EIA] lists equality and health inequality issues identified and how they
- 4 have been addressed, and explains why any populations were excluded from the
- 5 scope.

6 2 Activities, services or aspects of care covered by

7 the guideline update

- 8 We will look at the evidence and consider making new recommendations, or
- 9 updating existing recommendations, on methenamine hippurate as an alternative to
- antibiotic prophylaxis for treating recurrent UTI. For more information, see the <u>2022</u>
- 11 surveillance review decision.
- 12 For all other areas of the guideline:
- There will be no evidence review.
- We will retain the existing recommendations but we may revise them to ensure
- consistency and reflect current NICE style.

16 **3 Draft review questions**

- We have identified the following draft review question:
- 18 What is the clinical and cost effectiveness of methenamine hippurate when
- 19 compared to antibiotics in the prevention of recurrent UTIs for adults and
- 20 children?
- Note that guideline recommendations for medicines will normally fall within licensed
- indications; exceptionally, and only if clearly supported by evidence, use outside a
- 23 licensed indication may be recommended. The guideline will assume that prescribers
- 24 will use a medicine's summary of product characteristics to inform decisions made
- with individual patients.

4 Economic aspects

- 2 We will take economic aspects into account when making recommendations. We will
- 3 review the economic evidence and carry out economic analyses, using NHS
- 4 perspective, as appropriate.

5 NICE quality standards that may be affected by this

6 guideline update

- Urinary tract infections in adults (2015, updated 2023) NICE quality standard
- 8 QS90

1

- <u>Urinary tract infection in children and young people</u> (2013, updated 2022) NICE
- quality standard QS36

11 6 Further information

- NICE guidelines cover health and care in England. Decisions on how they apply in
- other UK countries are made by ministers in the Welsh Government, Scottish
- 14 Government and Northern Ireland Executive.

The guideline update is expected to be published in November 2024.

To follow the progress of the update, see the guideline in development page.

Our website has information about how NICE guidelines are developed.

© NICE 2024. All rights reserved. Subject to Notice of rights.

15